CH631169A5 - Method for preparing amides of (2-pyrimidinylthio)-alkanoic acids, having an antilipemic activity - Google Patents
Method for preparing amides of (2-pyrimidinylthio)-alkanoic acids, having an antilipemic activity Download PDFInfo
- Publication number
- CH631169A5 CH631169A5 CH317377A CH317377A CH631169A5 CH 631169 A5 CH631169 A5 CH 631169A5 CH 317377 A CH317377 A CH 317377A CH 317377 A CH317377 A CH 317377A CH 631169 A5 CH631169 A5 CH 631169A5
- Authority
- CH
- Switzerland
- Prior art keywords
- pyrimidinylthio
- alkyl
- general formula
- amides
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
Description
La presente invenzione riguarda metodi per preparare ammidi di acidi (2-pirimidiniltio)alcanoici dotate di attività antilipemica e i prodotti di tali metodi. The present invention relates to methods for preparing amides of alkanoic (2-pyrimidinylthio) acids having antilipemic activity and the products of these methods.
Acidi (2-pirimidiniltio)alcanoici, loro esteri, ammidi e idrazidi, sono descritti in U.S.P. 3 814 761, con riferimento a un effetto antilipemico. Le ammidi sostituite che costituiscono oggetto di questa domanda, strutturalmente nuove, risultano però nettamente meno tossiche — a parità di attività — dei composti descritti nel brevetto citato. Le ammidi della presente invenzione corrispondono alla formula generale (I) Alkanoic (2-pyrimidinylthio) acids, their esters, amides and hydrazides, are described in U.S.P. 3 814 761, with reference to an antilipemic effect. The replaced amides which are the subject of this application, structurally new, however, are clearly less toxic - with the same activity - than the compounds described in the cited patent. The amides of the present invention correspond to the general formula (I)
,/ , /
E IS
S-CH-(CHp) -CO-N' i n \ 3 S-CH- (CHp) -CO-N 'i n \ 3
E IS
(I) (THE)
nella quale in which
Y rappresenta alogeno; Y represents halogen;
R rappresenta idrogeno o alchile CVC4 R represents hydrogen or CVC4 alkyl
4 5 E E 4 5 E E
R1 rappresenta alogeno; un residuo — N R1 represents halogen; a residue - N
E IS
(dove R4=H o alchile CrC4, mentre R5 e R6, che possono essere uguali o diversi, stanno per H, alogeno, metile o metossile); un residuo benzilamminico; un residuo (where R4 = H or CrC4 alkyl, while R5 and R6, which can be the same or different, stand for H, halogen, methyl or methoxyl); a benzylamine residue; a residue
20 20
R1 rappresenta un residuo R1 represents a residue
(dove (where is it
25 R5 e R6 hanno i significati sopra precisati), o un residuo benzilamminico; 25 R5 and R6 have the meanings specified above), or a benzylamine residue;
n =0; n = 0;
R2 e R3, che possono essere uguali o diversi, rappresentano residui alchilici o alchenilici CrC10, lineari o ramificati; R2 and R3, which can be the same or different, represent linear or branched alkyl or alkenyl CrC10;
30 residui idrossialchilici o mercaptoalchilici c2-c5, lineari o ramificati; mentre R2 può anche rappresentare idrogeno. 30 c2-c5 hydroxyalkyl or mercaptoalkyl residues, linear or branched; while R2 can also represent hydrogen.
E" IS"
35 35
Esempi non limitativi di R1 sono i resìdui Non-limiting examples of R1 are residues
-HB^r -HB ^ r
40 corrispondenti alle seguenti ammine, anilina, 2,3-xilidina, 4-cloroanilina, 4-metossianilina, 2,4,6-trimetilanilina, 3,4-di-cloroanilina, 4-fluoroanilina, 3-trifluorometilanilina, 4-fenil-anilina; il residuo benzilamminico; i gruppi -NH-CH2CH2OH e -N-CH2CH2OH; e simili. 40 corresponding to the following amines, aniline, 2,3-xylidine, 4-chloroaniline, 4-methoxyaniline, 2,4,6-trimethylaniline, 3,4-di-chloroaniline, 4-fluoroaniline, 3-trifluoromethylaniline, 4-phenyl- aniline; the benzylamine residue; the groups -NH-CH2CH2OH and -N-CH2CH2OH; and similar.
45 45
CH, CH,
Secondo l'invenzione, i composti (I) si possono preparare facendo reagire i derivati attivati dei corrispondenti acidi (II) con le ammine di formula generale (III), secondo so lo schema A: According to the invention, the compounds (I) can be prepared by reacting the activated derivatives of the corresponding acids (II) with the amines of general formula (III), according to the scheme A:
Schema A Scheme A
55 55
60 60
ï Jl ï Jl
V-S-CH-(CH„) -COX 1 i 2'n V-S-CH- (CH „) -COX 1 i 2'n
+ H-H + H-H
/ /
\3 \ 3
(D (D
(II) (II)
(III) (III)
dove Y, R, R\ R2, R'en hanno i significati sopra precisati, mentre X rappresenta alogeno (di preferenza cloro) oppure 65 il residuo 0-C0-0C2H5. Quando (II) rappresenta un cloruro acilico (X = CI), quest'ultimo si ottiene per trattamento del corrispondente acido (2-pirimidiniltio)alcanoico con SOCl2 o cloruro di ossalile in soluzione benzenica; non oc- where Y, R, R \ R2, R'en have the meanings specified above, while X represents halogen (preferably chlorine) or 65 the residue 0-C0-0C2H5. When (II) represents an acyl chloride (X = CI), the latter is obtained by treating the corresponding alkanoic acid (2-pyrimidinylthio) with SOCl2 or oxalyl chloride in benzene solution; not oc-
631169 631169
4 4
corre isolare i composti (II) così ottenuti, che vengono direttamente trattati con le ammine (III), eventualmente in presenza di basi terziarie. Quando invece i composti (II) sono anidridi miste (X = 0-C0-0C2H5), si procede alla loro preparazione per trattamento dei corrispondenti acidi (2-pirimi-diniltio)alcanoici con clorocarbonato d'etile in presenza d'una base terziaria (di preferenza trietilammina), in solventi come tetraidrofurano, cloroformio o acetone; anche in questo caso il composto (II) può non venire isolato ed essere direttamente trasformato nel prodotto finale (I) mediante reazione con l'ammina (III) desiderata. it is necessary to isolate the compounds (II) thus obtained, which are directly treated with the amines (III), possibly in the presence of tertiary bases. When, on the other hand, the compounds (II) are mixed anhydrides (X = 0-C0-0C2H5), they are prepared by treating the corresponding alkanoic acids (2-pyrimi-dinylthio) with ethyl chlorocarbonate in the presence of a tertiary base (preferably triethylamine), in solvents such as tetrahydrofuran, chloroform or acetone; also in this case the compound (II) may not be isolated and be directly transformed into the final product (I) by reaction with the desired amine (III).
Alternativamente, i composti (I) si possono preparare trattando direttamente i corrispondenti acidi (2-pirimidinil-tio)alcanoici con due moli di ammina (III), due moli di trietilammina e due moli di BF3-eterato, in soluzione benze-nica o toluenica, a riflusso, anidrificando il solvente su MgS04, secondo la tecnica descritta da J. Tani, J. Dine e I. Inouf in Synthesis, 714,1975. Alternatively, the compounds (I) can be prepared by directly treating the corresponding alkanoic (2-pyrimidinyl-thio) acids with two moles of amine (III), two moles of triethylamine and two moles of BF3-etherate, in benzene solution or toluene, reflux, anhydrifying the solvent on MgS04, according to the technique described by J. Tani, J. Dine and I. Inouf in Synthesis, 714,1975.
R2 R2
Nel caso particolare in cui il gruppo -N^[ , nei com- In the particular case where the group -N ^ [, in the com-
R3 R3
posti di formula (I), rappresenta un residuo ß-idrossialchil-amminico, la preparazione può essere effettuata facendo reagire i corrispondenti acidi con aziridine di formula generale (IV) places of formula (I), represents a ß-hydroxyalkyl-amino residue, the preparation can be carried out by reacting the corresponding acids with aziridines of general formula (IV)
(IV) (IV)
R R
10 10
nella quale R9 e R10 rappresentano atomi di idrogeno o gruppi alchilici Cj-C3, e R10 può anche significare CH2CH2OH. wherein R9 and R10 represent hydrogen atoms or Cj-C3 alkyl groups, and R10 can also mean CH2CH2OH.
I composti (I) nei quali Y rappresenta cloro, mentre R1 ha un significato diverso da alogeno, si possono ottenere secondo l'invenzione trattando le ammidi di acidi (4,6-di-cIoro-2-pirimidiniltio)alcanoici (V) con due equivalenti di una ammina (VI), a fusione, secondo lo schema B: The compounds (I) in which Y represents chlorine, while R1 has a different meaning from halogen, can be obtained according to the invention by treating the amides of alkanoic acids (4,6-di-chIoro-2-pyrimidinylthio) alkanoic (V) with two equivalents of an amine (VI), fusion, according to scheme B:
Schema B Scheme B
io I
15 15
20 20
S—OH—(CH_) -CO-H S — OH— (CH_) -CO-H
2'31 2'31
E IS
\3 \ 3
(v) (V)
2 R'-H 2 R'-H
(VI) (YOU)
CI JT CI JT
y Ys-?h-(cVi y Ys-? h- (cVi
-CO-IT -CO-IT
/ /
XR3 XR3
(I) (THE)
dove R, R2, R3 e n hanno i significati sopra precisati, men-25 tre R1 ha i significati sopra precisati eccezion fatta per quello di alogeno. where R, R2, R3 and n have the above specified meanings, while R1 has the above specified meanings except for the halogen one.
A loro volta, gli acidi (4,6-dicloro-2-pirimidiniltio)alca-noici di formula generale (VII) si possono preparare me-mediante idrolisi acida dei corrispondenti esteri (VIII), ac-30 cessibili per esempio secondo il metodo descritto in U.S.P. 3 814 761 per condensazione del tiobarbiturato di sodio con bromoesteri (IX) e susseguente reazione con POCl3, secondo lo schema C: In turn, the alkanoic (4,6-dichloro-2-pyrimidinylthio) acids of general formula (VII) can be prepared by means of acid hydrolysis of the corresponding esters (VIII), ac-30 which can be dissolved for example according to the method described in USP 3 814 761 by condensation of sodium thiobarbiturate with bromoesters (IX) and subsequent reaction with POCl3, according to scheme C:
Schema C Scheme C
(Vili) (VIII)
(VII) (VII)
dove Ren hanno i significati sopra precisati, mentre Et rappresenta un residuo etilico. where Ren have the meanings specified above, while Et represents an ethyl residue.
I composti di questa invenzione sono tutti nettamente meno tossici del corrispondente acido libero. Ad esempio 60 la [4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-ß-idrossietil)-acetammide somministrata a dose singola per via orale nel topo non determina la morte di alcun animale né la comparsa di fenomeni tossici alla dose che corrisponde alla DL100 nel caso del corrispondente acido [4-cloro-6-(2,3-xili-65 dino)-2-pirimidiniltio] acetico. The compounds of this invention are all significantly less toxic than the corresponding free acid. For example 60 [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] - (N-ß-hydroxyethyl) -acetamide administered as a single oral dose in the mouse does not result in the death of any animal or the appearance of toxic phenomena at the dose corresponding to DL100 in the case of the corresponding acetic [4-chloro-6- (2,3-xyl-65 dino) -2-pyrimidinylthio] acetic acid.
In particolare, la [4-cloro-6-(2,3-xilidino)-2-pirimidinil-tio]-(N-ß-idrossietil)acetammide a 5 g/Kg/os non determina la morte di alcun animale nel ratto o nel topo, maschio o In particular, [4-chloro-6- (2,3-xylidino) -2-pyrimidinil-thio] - (N-ß-hydroxyethyl) acetamide at 5 g / Kg / os does not cause the death of any animal in the rat or in the mouse, male or
I THE
femmina, mentre l'acido [4-cloro-6-(2,3-xilidino)-2-pirimidi-niltio] acetico somministrato per via orale presenta nel topo maschio una DL50 di 1600 mg/Kg (1260-2032) e nella femmina una DL50 di 1155 mg/Kg (970-1374), calcolate secondo Litchfield e Wilcoxon. female, while the [4-chloro-6- (2,3-xylidino) -2-pyrimidi-niltio] acetic acid administered orally presents in the male mouse a LD50 of 1600 mg / Kg (1260-2032) and in the female a DL50 of 1155 mg / Kg (970-1374), calculated according to Litchfield and Wilcoxon.
Analogamente i composti corrispondenti alla formula generale Likewise the compounds corresponding to the general formula
CI CI
NH NH
CH. CH.
CH. CH.
in cui X è: -N(CH2-CH2OH)2; -NH(CH2CH2CH2OH); -NH(CH2CH2CH2CH2OH); -NHCH(CH3)CH2OH; -NH(CH2CH3); -NH(CH2CH2CH3); -NH(CH2CH2CH2CH3); -N(CH2CH3)2 non determinano a 5 g/Kg/os la morte di alcun animale. Ricerche tossicologiche a medio termine mostrano che a parità di dose la [4-cloro-6-(2,3-xilidino)-2--pirimidiniltio]-(N-ß-idrossietil)acetammide è meno tossica dell'acido [4-cloro-6-(2,3-xilidino)-2-pirimidiniltio] acetico, particolarmente a livello epatico. La notevole diminuzione di tossicità rilevata per i composti di questa invenzione, particolarmente quelli contenenti catene alchiliche o idrossi alchi-liche fino a 4 atomi di carbonio, non è seguita da alcuna diminuzione di attività, sempre in riferimento all'acido libero. Questi composti riducono la concentrazione di trigliceridi e colesterolo nel siero di sangue di ratti normali o di ratti trattati con dieta ipercolesterolemizzante. In particolare con il test di Buchanan (il farmaco è somministrato nel ratto normale per 4 giorni e l'analisi del colesterolo serico è istituita al quinto giorno) sono considerati attivi i composti che abbassano il colesterolo serico almeno del 20% ad una dose di 400 mg/Kg; un farmaco standard, rappresentato dal Clofibrate, alla dose di 200 mg/Kg riduce del 20% il livello del colesterolo serico. Con questo test al variare di X sono stati ottenuti i seguenti risultati: wherein X is: -N (CH2-CH2OH) 2; -NH (CH2CH2CH2OH); -NH (CH2CH2CH2CH2OH); -NHCH (CH3) CH2OH; -NH (CH2CH3); -NH (CH2CH2CH3); -NH (CH2CH2CH2CH3); -N (CH2CH3) 2 do not cause the death of any animal at 5 g / Kg / os. Medium-term toxicological research shows that [4-chloro-6- (2,3-xylidino) -2 - pyrimidinylthio] - (N-ß-hydroxyethyl) acetamide is less toxic than acid for the same dose. [4- chloro-6- (2,3-xylidino) -2-pyrimidinylthio] acetic, particularly in the liver. The considerable decrease in toxicity detected for the compounds of this invention, particularly those containing alkyl or hydroxy alkylic chains of up to 4 carbon atoms, is not followed by any decrease in activity, always with reference to free acid. These compounds reduce the concentration of triglycerides and cholesterol in the blood serum of normal rats or of rats treated with a hypercholesterolemic diet. In particular with the Buchanan test (the drug is administered in the normal rat for 4 days and the analysis of serum cholesterol is established on the fifth day) the compounds that lower the serum cholesterol by at least 20% at a dose of 400 are considered active mg / Kg; a standard drug, represented by Clofibrate, at a dose of 200 mg / Kg reduces the level of serum cholesterol by 20%. With this test, the following results were obtained when X was changed:
X X
dose: mg/kg dose: mg / kg
% diminuzione dei livelli del colesterolo serico oh % decrease in serum cholesterol levels oh
50 50
30,28 30,28
nhch2ch2oh nhch2ch2oh
56 56
30,70 30,70
n(ch2ch2oh)2 n (ch2ch2oh) 2
64 64
28,70 28,70
nhch(ch3)ch2oh NHCH (CH3) CH2OH
59 59
31,20 31,20
nh(ch2)3ch3 nh (ch2) 3ch3
58 58
35,00 35,00
nhch2ch3 nhch2ch3
54 54
24,20 24,20
n(c2h5)2 n (C2H5) 2
54 54
15,00 15,00
nhc3h, nhc3h,
56 56
21,00 21,00
nh(ch2)2ch2oh nh (ch2) 2ch2oh
50 50
15,00 15,00
nh(ch2)3ch2oh nh (ch2) 3ch2oh
50 50
19,00 19,00
631169 631169
Nel siero di sangue di ratti normali o in dieta ipercolesterolemizzante trattati con [4-cloro-6-(2,3-xilidino)-2-piri-midiniltio]-(N-ßidrossietil)acetammide, non compaiono steroidi abnormi eventualmente derivati dalle vie di sintesi del colesterolo. Si può usare da 10 a 200 mg di principio attivo come dose singola. Utili forme farmaceutiche possono essere: In the blood serum of normal rats or on a hypercholesterolemic diet treated with [4-chloro-6- (2,3-xylidino) -2-piri-midinylthio] - (N-ßhydroxyethyl) acetamide, there are no abnormal steroids possibly derived from the pathways of synthesis of cholesterol. 10 to 200 mg of active substance can be used as a single dose. Useful pharmaceutical forms can be:
— capsule: composizione per 100 mg [4-cloro-6-(2,3-xilidino)-2-pirimidiniltio](N-ß-idrossietil) acetammide mg 50 lattosio mg 49 magnesio stearato mg 1 - capsules: composition for 100 mg [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] (N-ß-hydroxyethyl) acetamide mg 50 lactose mg 49 magnesium stearate mg 1
— compresse: composizione per 100 mg [4-cloro-6-(2,3-xilidino)-2-pirimidiniltio](N-ß-idrossietil) - tablets: composition per 100 mg [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] (N-ß-hydroxyethyl)
acetammide mg acetamide mg
50 50
amido mg starch mg
27 27
lattosio mg lactose mg
18 18
talco mg talc mg
4 4
magnesio stearato mg magnesium stearate mg
1 1
Esempio 1 Example 1
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio ]-(N-&-idrossietil)-acetammide [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] - (N - & - hydroxyethyl) -acetamide
Alla sospensione di acido [4-cloro-6-(2,3-xilidino)-2--pirimidiniltio] acetico (60 g) in cloroformio (1200 mi) si aggiunge, gocciolando a temperatura ambiente, etilenimmi-na (5,4 mi) in cloroformio (60 mi) e si scalda all'ebollizione per 4 ore la soluzione ottenuta. Si raffredda a temperatura ambiente, si aggiungono altri 2,7 mi di etilenimmina in cloroformio (30 mi) e si scalda a ricadere ancora per 4 ore. To the suspension of [4-chloro-6- (2,3-xylidino) -2 - pyrimidinylthio] acetic acid (60 g) in chloroform (1200 ml), ethylenymine (5.4) is added dropwise at room temperature ml) in chloroform (60 ml) and the resulting solution is heated to boiling for 4 hours. The mixture is cooled to room temperature, a further 2.7 ml of ethylenimine are added in chloroform (30 ml) and heated to reflux again for 4 hours.
Dopo una ulteriore aggiunta di 1,35 mi di etilenimmina in cloroformio (15 mi) e un nuovo riscaldamento all'ebollizione per 4 ore, si concentra a piccolo volume (300 mi). Si filtra il solido precipitato che è successivamente cristallizzato da acetone. Si ottengono 40 g di [4-cloro-6-(2,3-xili-dino)-2-pirimidiniltio]-(N-ß-idroessietil)acetammide. After a further addition of 1.35 ml of ethylenimine in chloroform (15 ml) and re-heating to boiling for 4 hours, it is concentrated to a small volume (300 ml). The precipitated solid is filtered and subsequently crystallized from acetone. 40 g of [4-chloro-6- (2,3-xyl-dino) -2-pyrimidinylthio] - (N-ß-hydroxyethyl) acetamide are obtained.
Calcolato per C16H19C1N402S: C 52,36 H 5,22 N 15,28 Trovato: C 52,43 H 5,20 N 15,31 Calculated for C16H19C1N402S: C 52.36 H 5.22 N 15.28 Found: C 52.43 H 5.20 N 15.31
p.f. = 150-151°C (acetone). mp = 150-151 ° C (acetone).
Con lo stesso metodo sono stati preparati i seguenti composti: The following compounds were prepared with the same method:
Esempio 2 Example 2
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N,N-bis-$-idrossi-etil)acetammide [4-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N, N-bis - $ - hydroxy-ethyl) acetamide
Calcolato per C18H23C1N403S: C 52,59 H 5,64 N 13,64 Trovato: C 52,37 H 5,48 N 13,53 Calculated for C18H23C1N403S: C 52.59 H 5.64 N 13.64 Found: C 52.37 H 5.48 N 13.53
p.f. = 166-167°C (acetone). mp = 166-167 ° C (acetone).
Esempio 3 Example 3
[ 4-cloro-6-(2,3-xilidino)-2-pirimidiniltio ]-N-(ct-metil-fì--idrossietil)acetammide [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] -N- (ct-methyl-phi - hydroxyethyl) acetamide
Calcolato per C17H21C1N402S: C 53,58 H 5,56 N 14,72 Trovato: C 53,39 H 5,42 N 14,69 Calculated for C17H21C1N402S: C 53.58 H 5.56 N 14.72 Found: C 53.39 H 5.42 N 14.69
p.f. = 170-172°C (acetone). mp = 170-172 ° C (acetone).
5 5
5 5
10 10
lì there
20 20
25 25
30 30
35 35
40 40
45 45
50 50
55 55
60 60
65 65
631169 631169
6 6
Esempio 4 -2-pirimidiniltio] acetico, si ottiene con buone rese la corri- Example 4 -2-pyrimidinylthio] acetic, the correction is obtained with good yields
[4-cloro-6-(p-cloroanilino)-2-pirimidiniltio ]-(N-^-idrossi etil)- spondente N-ß-idrossietilammide. [4-chloro-6- (p-chloroaniline) -2-pyrimidinylthio] - (N - ^ - hydroxy ethyl) - N-ß-hydroxyethylamide coating.
acetammide Calcolato per CnH17ClN403S: C 41,19 H 5,34 N 17,46 acetamide Calculated for CnH17ClN403S: C 41.19 H 5.34 N 17.46
Calcolato per C14H14C12N402S: C 45,03 H 3,78 N 15,02 5 Trovat°: ^ c 41 >25 H 5>40 N 17'40 Calculated for C14H14C12N402S: C 45.03 H 3.78 N 15.02 5 Found: ^ c 41> 25 H 5> 40 N 17'40
Trovato: . C 44,95 H 3,80 N 15,07 pf" ~~ 119"121°c (acetato d'etile). Found: . C 44.95 H 3.80 N 15.07 pf "~~ 119" 121 ° c (ethyl acetate).
p.f. = 145-147°C (etanolo/acqua). mp = 145-147 ° C (ethanol / water).
Esempio 5 Example 5
Esempio 9 Example 9
/4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-ft-idrossietìl)-(5-cloro-6-benzilammino-2-pirimidiniltio)-(N-$-idrossietil)- acetammide acetammide / 4-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N-ft-hydroxyethyl) - (5-chloro-6-benzylamino-2-pirimidiniltio) - (N - $ - hydroxyethyl) - acetamide acetamide
Alla soluzione di acido [4-cloro-6-(2,3-xilidino)-2-piri-Calcolato per C15H17C1N402S: C 51,04 H 4,86 N 15,89 midiniltio] acetico (85 g), trietilammina (45 mi), in clorofor-Trovato: C 50,87 H 4,97 N 15,75 mj0 anidro (750 mi) raffreddata a —5° si gocciolano, sotto To the solution of [4-chloro-6- (2,3-xylidino) -2-piri-Calculated for C15H17C1N402S: C 51,04 H 4,86 N 15,89 midinylthio] acetic (85 g), triethylamine (45 ml), in chlorofor-Found: C 50.87 H 4.97 N 15.75 mj0 anhydrous (750 ml) cooled to -5 ° they drop, under
P-f- = H7-119°C (etanolo/acqua). 15 agitazione, 35 mi di clorocarbonato di etile e, successiva mente, 22 mi di etanolammino, mantenendo la temperatura Esempio 6 aj sotto di + 10°C. Si lava la miscela di reazione con P-f- = H7-119 ° C (ethanol / water). 15 stirring, 35 ml of ethyl chlorocarbonate and, subsequently, 22 ml of ethanolamine, keeping the temperature Example 6 aj below + 10 ° C. The reaction mixture is washed with
(4-cloro-6-anilino-2-pirimidiniltio)-(N-ß-idrossietil)- acqua (350 mi), si essicca su solfato di sodio e si elimina il acetammide solvente a pressione ridotta. Il residuo è lavato con benzolo (4-chloro-6-aniline-2-pyrimidinylthio) - (N-ß-hydroxyethyl) - water (350 ml), dried on sodium sulphate and the solvent acetamide was removed under reduced pressure. The residue is washed with benzene
20 (500 mi) e successivamente cristallizzato da acetone. Si ot-Calcolato per C14H15CIN402S: C 49,61 H 4,46 N 16,54 tengono 55 g di [4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-Trovato: C 49,50 H 4,64 N 16,45 (N-R-idrossietil)acetammide, identica al composto preparato p.f. — 136-138°C (etanolo/acqua). secondo l'esempio 1. 20 (500 ml) and subsequently crystallized from acetone. It is obtained by C14H15CIN402S: C 49.61 H 4.46 N 16.54 hold 55 g of [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] -Founded: C 49,50 H 4.64 N 16.45 (NR-hydroxyethyl) acetamide, identical to the compound prepared pf - 136-138 ° C (ethanol / water). according to example 1.
Esempio 7 25 Con lo stesso metodo sono stati preparati i seguenti com- Example 7 25 With the same method the following com- pounds were prepared
[4-cloro-6-(p-metossianilino)-2-pirimidiniltio ]-(N-$-idrossi- posti. [4-chloro-6- (p-methoxyaniline) -2-pyrimidinylthio] - (N - $ - hydroxy- places.
etil)acetammide ethyl) acetamide
Esempio 10 Example 10
Calcolato per C15H17C1N403S: C 48,82 H 4,65 N 15,20 ... - , ...,. , _ . . ... 7 ,,T , Calculated for C15H17C1N403S: C 48.82 H 4.65 N 15.20 ... -, ...,. , _. . ... 7 ,, T,
Trovato- C 48 95 H 4 64 N 15 12 30 l4-cloro-6-(2,3-xilidino)-2-pinmidiniltio]-(N-etil)acetammide p.f. = 119-121°C (etanolo/acqua). Calcolato per C16H19C1N40S: C 54,75 H 5,46 N 15,98 Found - C 48 95 H 4 64 N 15 12 30 l4-chloro-6- (2,3-xylidino) -2-pinmidinylthio] - (N-ethyl) acetamide m.p. = 119-121 ° C (ethanol / water). Calculated for C16H19C1N40S: C 54.75 H 5.46 N 15.98
Trovato: C 54,61 H 5,50 N 15,87 Found: C 54.61 H 5.50 N 15.87
Esempio 8 p.f. = 191-192°C (acetone). Example 8 m.p. = 191-192 ° C (acetone).
a) [4-cloro-6-(N-metil-N-fì-idrossietilammino)-2-pirimidinil- a) [4-chloro-6- (N-methyl-N-phi-hydroxyethylamino) -2-pyrimidinyl-
tio]acetato d'etile 35 „ . ,, thio] ethyl acetate 35 ". ,,
Esempio 11 Example 11
La miscela di (4,6-dicloro-2-pirimidiniltio)acetato di etile [4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-n-pwpil)-(g 16), carbonato di sodio anidro (g 3,7), N-metilammino- acetammide The mixture of (4,6-dichloro-2-pyrimidinylthio) ethyl acetate [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] - (Nn-pwpil) - (g 16), carbonate of anhydrous sodium (3.7 g), N-methylaminoacetamide
-etanolo (mi 5,9) di etanolo (100 mi) è scaldata all'ebollizione, sotto agitazione, per 16 ore. Si filtra ed al filtrato si 40 Calcolato per C17H21ClN4OS: C 55,93 H 5,80 N 15,36 aggiunge acqua fino ad innescare la precipitazione (400 mi). Trovato: C 55,75 H 5,60 N 15,47 ethanol (5.9 ml) of ethanol (100 ml) is heated to boiling, under stirring, for 16 hours. The mixture is filtered and 40 is calculated for C17H21ClN4OS: C 55.93 H 5.80 N 15.36 adds water until the precipitation is triggered (400 ml). Found: C 55.75 H 5.60 N 15.47
Si lascia a riposo per 60' a 0°C. Si filtra il solido precipitato p.f. = 146-148°C (benzene). It is left to rest for 60 'at 0 ° C. The precipitated solid is filtered m.p. = 146-148 ° C (benzene).
che è ricristallizato da etanolo/acqua. Si ottengono 13 g di [4-cloro-6-(N-metil-N-ß-idrossietilammino)-2-pirimidiniltio]- which is recrystallized from ethanol / water. 13 g of [4-chloro-6- (N-methyl-N-ß-hydroxyethylamino) -2-pyrimidinylthio] are obtained -
acetato d'etile. 45 Esempio 12 ethyl acetate. 45 Example 12
Calcolato per CnH16N3C103S: C 43,18 H 5,28 N 13,75 14-cloro-6f,3-xilidino)-2-pirìmidiniltio]-(N-i-propil)- Calculated for CnH16N3C103S: C 43.18 H 5.28 N 13.75 14-chloro-6f, 3-xylidino) -2-pyrìmidinylthio] - (N-i-propil) -
Trovato: C 43,20 H 5,38 N 13,68 acetamfnlde p.f. = 73-74°C (etere isopropilico). Calcolato per C17H21ClN4OS: C 55,93 H 5,80 N 15,36 Found: C 43.20 H 5.38 N 13.68 acetamfnlde m.p. = 73-74 ° C (isopropyl ether). Calculated for C17H21ClN4OS: C 55.93 H 5.80 N 15.36
50 Trovato: C 56,06 H 5,96 N 15,24 50 Found: C 56.06 H 5.96 N 15.24
b) Acido [4-cloro-6-(N-metil-N-$-idrossietilammino)-2- p.f. = 156-158°C (benzene). b) Acid [4-chloro-6- (N-methyl-N - $ - hydroxyethylamino) -2- m.p. = 156-158 ° C (benzene).
-pirìmidiniltio ]acetico -pyrimidinylthio] acetic
La soluzione di 5,6 g dell'estere sopra descritto in 30 mi Esempio 13 The 5.6 g solution of the ester described above in 30 ml Example 13
di etanolo, addizionata di 0,7 g di NaOH in 8 mi di acqua, of ethanol, added with 0.7 g of NaOH in 8 ml of water,
viene bollita per due minuti, poi diluita con 160 mi d'acqua 55 [4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-n-butil)-ed estratta con etere. La fase acquosa è acidificata con acetammide it is boiled for two minutes, then diluted with 160 ml of water 55 [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] - (N-n-butyl) -and extracted with ether. The aqueous phase is acidified with acetamide
17,6 mi di HCl IN ed evaporata a secchezza. Per cristalliz- Calcolato per C18H23N4C10S: C 57,03 H 6,12 N 14,79 zazione del residuo da circa 60 mi di acetone si ottengono Trovato- C 56 90 H 6 15 N 14,70 17.6 ml of HCl IN and evaporated to dryness. By crystallization - Calculated for C18H23N4C10S: C 57.03 H 6.12 N 14.79 zation of the residue from about 60 ml of acetone are obtained Found - C 56 90 H 6 15 N 14.70
4 g dell'acido desiderato. p.f. = 137-139°C (etere etiUco). 4 g of the desired acid. mp = 137-139 ° C (ethereal ether).
Calcolato per C9Hi2ClN303S: C 38,90 H 4,36 N 15,14 60 Calculated for C9Hi2ClN303S: C 38.90 H 4.36 N 15.14 60
Trovato:. C39,05 H4,30 N 15,10 Esempio 14 Found:. C39.05 H4.30 N 15.10 Example 14
p.f. = 188-190°C (acetone). mp = 188-190 ° C (acetone).
[4-cloro-6-(2,3-xilidino)-2-pirìmidiniltio ]-(N-n-esil)- [4-chloro-6- (2,3-xylidino) -2-pyrìmidinylthio] - (N-n-hexyl) -
c) [4-cloro-6-(N-metil-N-ß-idrossietilammino)-2-pirimidinil- acetammide tio]-(N-$-idrossietil)acetammide 65 Calcolato per C20H27C1N4OS: C 59,00 H 6,69 N 13,77 c) [4-chloro-6- (N-methyl-N-ß-hydroxyethylamino) -2-pyrimidinyl- acetamide thio] - (N - $ - hydroxyethyl) acetamide 65 Calculated for C20H27C1N4OS: C 59.00 H 6.69 N 13.77
Operando secondo l'esempio 1, per reazione di etilen- Trovato: C 59,15 H 6,52 N 13,80 Operating according to Example 1, by reaction of ethylene. Found: C 59.15 H 6.52 N 13.80
immina con acido t4-cloro-6-(N-metil-N-|ß-idrossietilammino)- p.f. = 116-118°C (benzene-esano). imine with t4-chloro-6- acid (N-methyl-N- | ß-hydroxyethylamino) - m.p. = 116-118 ° C (benzene-hexane).
7 7
631169 631169
Esempio 15 Example 15
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-n-ottil)-acetammide [4-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N-n-octyl) acetamide
Calcolato per C22H31C1N40S: C 60,71 H 7,23 N 12,89 Calculated for C22H31C1N40S: C 60.71 H 7.23 N 12.89
Trovato: C 60,85 H 7,35 N 12,78 Found: C 60.85 H 7.35 N 12.78
p.f. = 144-146°C (benzene). mp = 144-146 ° C (benzene).
Esempio 16 Example 16
[4-cloro-6-(2,3-xilidino)-2-pirìmidiniltio]-(N-allil)acetarnmide [4-chloro-6- (2,3-xylidino) -2-pirìmidiniltio] - (N-allyl) acetarnmide
Calcolato per C1TH19C1N40S: C 56,24 H 5,28 N 15,45 Trovato: C 56,35 H 5,25 N 15,47 Calculated for C1TH19C1N40S: C 56.24 H 5.28 N 15.45 Found: C 56.35 H 5.25 N 15.47
p.f. = 143-145°C (benzene/esano). mp = 143-145 ° C (benzene / hexane).
Esempio 17 Example 17
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-cicloesil)-acetammide [4-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N-cyclohexyl) acetamide
Calcolato per C20H25C1N4OS: C 59,30 H 6,23 N 13,84 Trovato: C 59,43 H 6,35 N 13,72 Calculated for C20H25C1N4OS: C 59.30 H 6.23 N 13.84 Found: C 59.43 H 6.35 N 13.72
p.f. = 156-158°C (acetone). mp = 156-158 ° C (acetone).
Esempio 18 Example 18
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio ]-(N,N-dietil)-acetammide [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] - (N, N-diethyl) -acetamide
Calcolato per C18H23ClN4OS: C 57,03 H 6,12 N 14,79 Trovato: C 57,29 H 6,07 N 14,68 Calculated for C18H23ClN4OS: C 57.03 H 6.12 N 14.79 Found: C 57.29 H 6.07 N 14.68
p.f. = 104-106°C (acetato di etile/esano). mp = 104-106 ° C (ethyl acetate / hexane).
Esempio 19 Example 19
l4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N~$-tioletil)-acetammide l4-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N ~ $ -tioletil) acetamide
Calcolato per C16H19ClN4OS2: C 50,16 H 5,00 N 14,64 Trovato: C 50,25 H 5,05 N 14,51 Calculated for C16H19ClN4OS2: C 50.16 H 5.00 N 14.64 Found: C 50.25 H 5.05 N 14.51
p.f. = 117-119°C (acetato di etile/esano). mp = 117-119 ° C (ethyl acetate / hexane).
Esempio 20 Example 20
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-morfolino)-acetammide [4-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N-morpholino) acetamide
Calcolato per C18H21N4C102S: C 55,00 H 5,39 N 14,27 Trovato: C 55,05 H 5,48 N 14,13 Calculated for C18H21N4C102S: C 55.00 H 5.39 N 14.27 Found: C 55.05 H 5.48 N 14.13
p.f. = 106-108°C (acetato di etile/esano). mp = 106-108 ° C (ethyl acetate / hexane).
Esempio 21 Example 21
14-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-piperidino)-acetammide 14-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N-piperidino) -acetamide
Calcolato per C19H23N4C10S: C 58,35 H 5,93 N 14,34 Trovato: C 58,20 H 5,83 N 14,27 Calculated for C19H23N4C10S: C 58.35 H 5.93 N 14.34 Found: C 58.20 H 5.83 N 14.27
p.f. = 113-115°C (cloruro di metilene/esano). mp = 113-115 ° C (methylene chloride / hexane).
Esempio 22 Example 22
[4-cloro-6-(2,3-xilidino)-2-pìrimidiniltio]-(N-3-idrossipropil)-acetammide [4-chloro-6- (2,3-xylidino) -2-pìrimidiniltio] - (N-3-hydroxypropyl) -acetamide
Calcolato per CnH21ClN402S: C 53,58 H 5,56 N 14,72 Trovato: C 53,48 H 5,45 N 14,70 Calculated for CnH21ClN402S: C 53.58 H 5.56 N 14.72 Found: C 53.48 H 5.45 N 14.70
p.f. = 122-124°C (acetato di etile). mp = 122-124 ° C (ethyl acetate).
Esempio 23 Example 23
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-4-idrossibutìl)-acetammide [4-chloro-6- (2,3-xylidino) -2-pirimidiniltio] - (N-4-hydroxybutyl) acetamide
Calcolato per C18H23CIN402S: C 54,72 H 5,87 N 14,19 Calculated for C18H23CIN402S: C 54.72 H 5.87 N 14.19
Trovato: C 54,68 H 5,75 N 14,25 Found: C 54.68 H 5.75 N 14.25
p.f. = 84-86°C (acetato di etile). mp = 84-86 ° C (ethyl acetate).
Sempre secondo il metodo descritto nell'esempio 9 sono stati inoltre ripreparati i composti degli esempi 2-7. Still according to the method described in Example 9, the compounds of Examples 2-7 were also prepared.
Esempio 24 Example 24
[4-cloro-6-(2,3-xilidino)-2-pirimidiniltio]-(N-n-bu til)-acetammide [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] - (N-n-bu til) -acetamide
La miscela di acido [4-cloro-6-(2,3-xilidino)-2-pirimidinil-tio]acetico (1,6 g), trietilammina (1,4 mi), n-butilammina (730 mg), trifluoruro di boro-eterato al 47 % (2,68 mi), in benzolo anidro (70 mi), è scaldata alla ebollizione per 24 ore. Il solvente di reazione viene disidratato facendolo passare in un estrattore Soxlet contenente solfato di magnesio. Si lava la miscela di reazione con NaOH al 10%, poi con acido cloridrico ed infine con acqua fino a neutralità. Si anidrifica su solfato di sodio e si evapora il solvente sotto vuoto. Il composto ottenuto è identico a quello dell'esempio 13. The mixture of [4-chloro-6- (2,3-xylidino) -2-pyrimidinyl-thio] acetic acid (1.6 g), triethylamine (1.4 ml), n-butylamine (730 mg), trifluoride of 47% boron etherate (2.68 ml), in anhydrous benzene (70 ml), is heated to boiling for 24 hours. The reaction solvent is dehydrated by passing it in a Soxlet extractor containing magnesium sulfate. The reaction mixture was washed with 10% NaOH, then with hydrochloric acid and finally with water until neutral. The mixture is dried over sodium sulphate and the solvent is evaporated under vacuum. The compound obtained is identical to that of Example 13.
Esempio 25 Example 25
a) Acido (4,6-dicloro-2-pirimidiniltio)acetico a) Acetic acid (4,6-dichloro-2-pyrimidinylthio)
La soluzione dell'estere etilico dell'acido (4,6-dicloro-2--pirimidiniltio)acetico (4 g) in una miscela di acido acetico glaciale (40 mi) e HCl al 37 % (8 mi) è scaldata alla ebollizione per tre ore. Dopo raffreddamento a 0°C si aggiungono acqua e ghiaccio e si filtra il solido precipitato. Questo ultimo è purificato estraendo con etere la soluzione acquosa del suo sale sodico che alla fine viene acidificata per filtrare nuovamente l'acido che è lavato con acqua al neutro e seccato sotto vuoto su P205. Per cristallizzazione da cloroformio si ottengono 2,5 g di acido (4,6-dicloro-2-pirimidi-niltio)acetico. The solution of the ethyl ester of the acetic acid (4,6-dichloro-2-pyrimidinylthio) (4 g) in a mixture of glacial acetic acid (40 ml) and 37% HCl (8 ml) is heated to boiling for three hours. After cooling to 0 ° C, water and ice are added and the precipitated solid is filtered. The latter is purified by extracting the aqueous solution of its sodium salt with ether which is then acidified to filter again the acid which is washed with water in neutral and dried under vacuum on P205. By crystallization from chloroform 2.5 g of acetic acid (4,6-dichloro-2-pyrimidi-nylthio) are obtained.
Calcolato per C6H4C12N2S02: C 30,12 H 1,68 N 11,72 Trovato: ■ C 30,20 H 1,69 N 11,61 Calculated for C6H4C12N2S02: C 30.12 H 1.68 N 11.72 Found: ■ C 30.20 H 1.69 N 11.61
p.f. = 120-122°C (cloroformio). mp = 120-122 ° C (chloroform).
b) (4,6-dicloro~2-pirimidiniltio)-(N-fì-idrossietil)acetammide b) (4,6-dichloro ~ 2-pyrimidinylthio) - (N-phi-hydroxyethyl) acetamide
Alla sospensione di acido (4,6-dicloro-2-pirimidiniltio)-acetico (2,390 g) in benzene anidro (24 mi) si aggiungono, gocciolando a temperatura ambiente, 1,27 mi di cloruro di ossalile in benzene anidro (6 mi). Si scalda, sotto agitazione, la miscela di reazione a 40°C per 30', quindi la si mantiene a 60°C per altri 10'. Si evapora il solvente sotto vuoto ottenendo un residuo oleoso che è ripreso con cloroformio anidro (50 mi); la soluzione cloroformica è aggiunta, goccia a goccia, ad una soluzione di etanolammina (1,1 mi) in cloroformio anidro (40 mi), mantenendo la temperatura a circa 15°C. Si lascia a riposo a temperatura ambiente per 60', To the suspension of (4,6-dichloro-2-pyrimidinylthio) -acetic acid (2,390 g) in anhydrous benzene (24 ml), 1.27 ml of oxalyl chloride in anhydrous benzene (6 ml) are added dropwise at room temperature ). The reaction mixture is heated under stirring at 40 ° C for 30 ', then it is kept at 60 ° C for another 10'. The solvent is evaporated under vacuum to obtain an oily residue which is taken up with anhydrous chloroform (50 ml); the chloroform solution is added drop by drop to an ethanolamine solution (1.1 ml) in anhydrous chloroform (40 ml), keeping the temperature at about 15 ° C. It is left to rest at room temperature for 60 ',
quindi si filtra il solido separatosi. Si evapora il filtrato sotto vuoto ottenendo un residuo che è cristallizzato da acetato di etile/esano (g 1,5). then the separated solid is filtered. The filtrate is evaporated under vacuum to obtain a residue which is crystallized from ethyl acetate / hexane (1.5 g).
Calcolato per C8H9N3C12S02: C 34,03 H 3,19 N 14,90 Trovato: C 34,12 H 3,22 N 14,85 Calculated for C8H9N3C12S02: C 34.03 H 3.19 N 14.90 Found: C 34.12 H 3.22 N 14.85
p.f. = 95-96°C (acetato di etile/esano). mp = 95-96 ° C (ethyl acetate / hexane).
Con lo stesso metodo sono stati preparati: With the same method were prepared:
Esempio 26 Example 26
(4,6-dicloro-2-pirimidiniltio)-(N-fì-tioletil)acetammide (4,6-dichloro-2-pirimidiniltio) - (N-.beta.-tioletil) acetamide
Calcolato per C8H9C12N3S20: C 32,20 H 3,02 N 14,10 Trovato: C 32,30 H 3,06 N 14,20 Calculated for C8H9C12N3S20: C 32.20 H 3.02 N 14.10 Found: C 32.30 H 3.06 N 14.20
p.f. = 88-90°C (acetato di etile/esano). mp = 88-90 ° C (ethyl acetate / hexane).
5 5
10 10
15 15
20 20
25 25
30 30
35 35
40 40
45 45
50 50
55 55
60 60
65 65
I * I *
631169 631169
Esempio 27 (4,6-dicloro-2~pirìmidìniltio)-(N-butil)acetammide Example 27 (4,6-dichloro-2 ~ pyrìmidìniltio) - (N-butyl) acetamide
Calcolato per C10H13C12N3SO: C 40,80 H 4,46 N 14,29 Trovato: C 40,91 H 4,42 N 14,29 Calculated for C10H13C12N3SO: C 40.80 H 4.46 N 14.29 Found: C 40.91 H 4.42 N 14.29
p.f. = 109-111°C (acetato di etile/esano). mp = 109-111 ° C (ethyl acetate / hexane).
Esempio 28 Example 28
[ 4-cloro-6-(2,3-xilidino)-2-pirimidiniltio ]-(N-$-idrossietil)-acetammide [4-chloro-6- (2,3-xylidino) -2-pyrimidinylthio] - (N - $ - hydroxyethyl) -acetamide
Una miscela di (4,6-dicloro-2-pirimidiniltio)-(N-ß-idrossi-etil)acetammide, ottenuta secondo l'esempio 25, (0,490 g) e 2,3-dimetilanilina (0,434 mi) è scaldata a fusione immergendola in un bagno ad olio (T = 110°C) per 10'. Il residuo 5 solido così ottenuto è raffreddato e cristallizzato da acetone ottenendo 0,400 g di [4-cloro-6-(2,3-xilidino)-2-pirimidiniI-tio]-(N-|ß-idrossietil)acetammide, identica a quella preparata secondo l'esempio 1. A mixture of (4,6-dichloro-2-pyrimidinylthio) - (N-ß-hydroxy-ethyl) acetamide, obtained according to example 25, (0.490 g) and 2.3-dimethylaniline (0.434 ml) is heated to melting by immersing it in an oil bath (T = 110 ° C) for 10 '. The solid residue 5 thus obtained is cooled and crystallized from acetone to obtain 0.400 g of [4-chloro-6- (2,3-xylidino) -2-pyrimidiniI-thio] - (N- | ß-hydroxyethyl) acetamide, identical to the one prepared according to example 1.
Con lo stesso metodo sono stati inoltre ripreparati i 10 composti degli esempi da 2 a 7 e da 10 a 23. The 10 compounds of Examples 2 to 7 and 10 to 23 were also prepared with the same method.
v v
Claims (3)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT21317/76A IT1063074B (en) | 1976-03-17 | 1976-03-17 | ACID AMIDES (Z-PYRIMIDINYLTI) AL CANOICS AS ANTI-LIPEMIC AGENTS |
Publications (1)
Publication Number | Publication Date |
---|---|
CH631169A5 true CH631169A5 (en) | 1982-07-30 |
Family
ID=11180012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH317377A CH631169A5 (en) | 1976-03-17 | 1977-03-14 | Method for preparing amides of (2-pyrimidinylthio)-alkanoic acids, having an antilipemic activity |
Country Status (14)
Country | Link |
---|---|
JP (1) | JPS52113983A (en) |
BE (1) | BE852401A (en) |
CA (1) | CA1081230A (en) |
CH (1) | CH631169A5 (en) |
DE (1) | DE2711149C3 (en) |
DK (1) | DK143558C (en) |
ES (1) | ES456902A1 (en) |
FR (1) | FR2344545A1 (en) |
GB (1) | GB1532195A (en) |
IT (1) | IT1063074B (en) |
MX (1) | MX4818E (en) |
NL (1) | NL166933C (en) |
PH (1) | PH14865A (en) |
SE (1) | SE434743B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5810525Y2 (en) * | 1978-08-04 | 1983-02-25 | 三菱電機株式会社 | small vacuum cleaner |
IT1211096B (en) * | 1981-08-20 | 1989-09-29 | Lpb Ist Farm | PYRIMIDINES AND S.TRIAZINICS HYPOLIPIDEMIZING ADAPTITY. |
JPS59199673A (en) * | 1983-04-25 | 1984-11-12 | Sumitomo Chem Co Ltd | Nitrogen-containing heterocyclic compound, its preparation and pesticide containing the same |
FR2636064B1 (en) * | 1988-09-08 | 1990-12-07 | Fabre Sa Pierre | THIOFORMAMIDINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
EP1399426A2 (en) * | 2001-06-12 | 2004-03-24 | Active Pass Pharmaceuticals, Inc. | Compounds, compositions and methods for modulating beta-amyloid production |
-
1976
- 1976-03-17 IT IT21317/76A patent/IT1063074B/en active
-
1977
- 1977-02-23 PH PH19485A patent/PH14865A/en unknown
- 1977-03-08 CA CA273,420A patent/CA1081230A/en not_active Expired
- 1977-03-14 CH CH317377A patent/CH631169A5/en not_active IP Right Cessation
- 1977-03-14 BE BE2055735A patent/BE852401A/en not_active IP Right Cessation
- 1977-03-15 GB GB10995/77A patent/GB1532195A/en not_active Expired
- 1977-03-15 FR FR7707617A patent/FR2344545A1/en active Granted
- 1977-03-15 SE SE7702922A patent/SE434743B/en unknown
- 1977-03-15 DE DE2711149A patent/DE2711149C3/en not_active Expired
- 1977-03-16 JP JP2811277A patent/JPS52113983A/en active Granted
- 1977-03-16 DK DK114377A patent/DK143558C/en not_active IP Right Cessation
- 1977-03-16 MX MX775544U patent/MX4818E/en unknown
- 1977-03-16 ES ES456902A patent/ES456902A1/en not_active Expired
- 1977-03-16 NL NL7702821.A patent/NL166933C/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FR2344545B1 (en) | 1980-03-21 |
GB1532195A (en) | 1978-11-15 |
DE2711149C3 (en) | 1980-12-11 |
DK143558C (en) | 1982-03-22 |
MX4818E (en) | 1982-10-20 |
IT1063074B (en) | 1985-02-11 |
NL7702821A (en) | 1977-09-20 |
JPS52113983A (en) | 1977-09-24 |
CA1081230A (en) | 1980-07-08 |
SE434743B (en) | 1984-08-13 |
DK143558B (en) | 1981-09-07 |
BE852401A (en) | 1977-07-01 |
ES456902A1 (en) | 1978-01-16 |
DK114377A (en) | 1977-09-18 |
DE2711149A1 (en) | 1977-09-29 |
SE7702922L (en) | 1977-09-18 |
FR2344545A1 (en) | 1977-10-14 |
PH14865A (en) | 1982-01-08 |
DE2711149B2 (en) | 1980-04-24 |
NL166933C (en) | 1981-10-15 |
JPS554746B2 (en) | 1980-01-31 |
NL166933B (en) | 1981-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DD273833A5 (en) | N 9 - CYCLOPENTYL SUBSTITUTED ADENINE DERIVATIVES | |
JPS604815B2 (en) | proline derivative | |
DD282690A5 (en) | PROCESS FOR THE PREPARATION OF THIENOPYRIDINONES | |
US3567777A (en) | 4-chloro-5-sulfamyl salicylic acid-(2',6'-dimethyl) anilide | |
EP0071935B1 (en) | 1-phenyl-2-aminocarbonylindole compounds, process and intermediates for their preparation and medicines containing them | |
CH631169A5 (en) | Method for preparing amides of (2-pyrimidinylthio)-alkanoic acids, having an antilipemic activity | |
EP0116360A1 (en) | 1-Phenyl-2-aminocarbonyl indoles, their preparation and medicines containing them | |
DE2747369C2 (en) | ||
US3600393A (en) | Dialkylamino alkylamino pyrazolo (3,4b) quinolines | |
EP0124893A2 (en) | Pyrimidone derivatives | |
EP0035868A1 (en) | Bicyclic compounds, their production and use | |
US5177069A (en) | Naphthysulfonylalkanoic acid compounds and pharmaceutical compositions thereof | |
US4483991A (en) | Hypotensive agents | |
Lawson et al. | 574. Some new mesoionic compounds | |
CH632748A5 (en) | METHOD FOR PRODUCING URACIL DERIVATIVES. | |
US4188484A (en) | (2-Pyrimidinyl-thio)-alkanoic acid amides and their preparation | |
Morozowich et al. | Prostaglandin prodrugs I: Stabilization of dinoprostone (prostaglandin E2) in solid state through formation of crystalline C1‐phenyl esters | |
CH622777A5 (en) | ||
US3712889A (en) | Oxodihydrobenzothiazine-s-dioxides | |
EP0019157A1 (en) | 5,6-Dihydro-11-alkylene-morphanthridin-6-ones and process for their preparation | |
US4185104A (en) | Tranquillizing complexes | |
FI61190C (en) | REFERENCE FOR THERAPEUTIC ADMINISTRATION OF THERAPEUTIC ANVAENDBARA 6- (PIPERAZIN-1-YL) CARBONYLOXY-8-OXO-3,4,7,8-TETRAHYDRO-2H 6H- (1,4) -DITIEPINO (2,3-C) -PYRRODE DERIVATIVES | |
DE2030714A1 (en) | New Tricychic Compounds and Processes for Their Preparation | |
US3595861A (en) | Novel synthesis of 2-quinazolinepropionic acids and derivatives | |
EP0019587B1 (en) | Carboxylic acid hydrazides, process for their preparation, their use and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |